Productivity Loss of Rheumatoid Arthritis Patients according to the Their Stages of the Disease Activity Score.
10.4078/jrd.2018.25.2.122
- Author:
Sang Cheol BAE
1
;
Jin Hye CHA
;
Jung Yoon CHOE
;
Sung Jae CHOI
;
Soo Kyung CHO
;
Won Tae CHUNG
;
Chung Il JOUNG
;
Young Ok JUNG
;
Young Mo KANG
;
Dong Wook KIM
;
Jinseok KIM
;
Young Joo KIM
;
Choong Ki LEE
;
Hye Soon LEE
;
Jisoo LEE
;
Sang Heon LEE
;
Sang Hoon LEE
;
Shin Seok LEE
;
Yeon Ah LEE
;
Seong Su NAH
;
Seung Cheol SHIM
;
Gwan Gyu SONG
;
Chang Hee SUH
;
Soyoung WON
;
Wan Hee YOO
;
Bo Young YOON
Author Information
1. Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea. scbae@hanyang.ac.kr
- Publication Type:Original Article
- Keywords:
Rheumatoid arthritis;
Productivity loss;
Disease activity score;
Patient reported outcome measures
- MeSH:
Arthritis, Rheumatoid*;
Efficiency*;
Female;
Humans;
Odds Ratio;
Outcome Assessment (Health Care);
Work Performance;
World Health Organization
- From:Journal of Rheumatic Diseases
2018;25(2):122-130
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: Productivity loss was compared by 3-stage of disease activity and associations between higher disease activity and high productivity loss were identified. METHODS: Data were extracted from Rheumatoid Arthritis (RA) Patient-reported Outcomes Research, which enrolled 2,000 RA patients (>20-year) on disease-modifying-antirheumatic-drugs (DMARDs) (≥6-month) from December 2012 to June 2013. This included 1,457 RA patients with the disease activity score (DAS-28-ESR) in their medical charts. Productivity loss in time and indirect cost was estimated using The World Health Organization Health and Work Performance Questionnaire (HPQ). Baseline characteristics and productivity loss outcomes were compared according to DAS-28-ESR groups. RESULTS: 84.4% were females, 54.2% had low DAS-28-ESR ( < 3.2), and 38.2% and 7.6% had moderate (3.2∼5.1) and high DAS-28-ESR (>5.1). Patients with moderate to high DAS-28-ESR had higher lost productivity time (LPT) and monthly costs of LPT than those with low DAS-28-ESR (time in hours: 110.0±58.4 vs. 132.4±57.2 vs. 71.5±52.0, p < 0.0001; monthly costs of LPT in 1,000 Korean won: 1,097±607 vs. 1,302±554 vs. 741±531, p < 0.0001). Multiple regression analyses revealed significant associations with high LPT in high (adjusted odds ratio [OR]=3.87, 95% confidence interval [CI]: 2.18∼6.87) and moderate DAS-28-ESR (adjusted OR=1.88, 95% CI: 1.41∼2.52) compared to low DAS-28-ESR. In addition, positive associations with high monthly costs of LPT were observed in high (adjusted OR=3.45, 95% CI: 1.98∼5.99) and moderate DAS-28-ESR (adjusted OR=1.93, 95% CI: 1.43∼2.54) compared to low DAS-28-ESR. CONCLUSION: Timely therapeutic strategies should be taken into consideration given that the RA patients with moderate to high DAS-28-ESR showed strong associations with high productivity loss for effective management of RA.
